文献速递基础与转化研究临床试验与 GCP

CRISPR-Cas12a编辑HBG1和HBG2启动子治疗β地中海贫血

CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia.
PubMed 文献 · N Engl J Med · 2026-01-01

该1-2期多中心开放标签单组研究评估reni-cel(CRISPR-Cas12a编辑自体造血干细胞)治疗输血依赖型β地中海贫血,9例受试者均实现中性粒细胞和血小板植入,至末次随访均无需输血,6例可评估者在12个月以上保持输血独立。

要点

  • reni-cel治疗使9例输血依赖型β地中海贫血患者全部摆脱输血。
  • 6例可评估者在12个月以上维持输血独立。
  • 不良事件总体与清髓预处理一致,4例报告6起严重不良事件。

核心结论

  • reni-cel治疗可快速实现中性粒细胞植入、增加胎儿血红蛋白表达并达到输血独立。

研究设计与样本

  • 1-2期、多中心、开放标签、单组研究,纳入18至35岁输血依赖型β地中海贫血患者。
  • 受试者接受白消安清髓预处理后输注reni-cel,主要终点为42天内中性粒细胞植入及不良事件频率和严重程度。
  • 研究因申办方重新评估临床开发优先级而提前终止,报告的是非预设分析结果。

主要发现

  • 9例受试者(4例β0/β0或β0/β0样,5例非β0/β0基因型)接受reni-cel并纳入分析,中位随访17.5个月(范围3.8至23.4)。
  • 全部9例受试者在输注后42天内实现中性粒细胞和血小板植入。
  • 9例受试者在末次随访时均无需输血,6例可评估者在12个月或更长时间保持输血独立。
  • 第6至18个月期间平均总血红蛋白水平大于12 g/dL,平均胎儿血红蛋白水平大于11 g/dL。
  • 9例受试者报告69起3级或4级不良事件(发生于reni-cel输注期间或之后新发或加重),4例报告6起严重不良事件(感染、发热或肺炎)。

关键数值与推荐

  • 主要终点包括输注后42天内中性粒细胞植入以及不良事件频率和严重程度。

临床怎么用

  • 数据支持进一步研究Cas12a基因编辑HBG1和HBG2启动子治疗输血依赖型β地中海贫血。

局限性

  • 研究提前终止,报告的是非预设分析结果,样本量小(9例)。
  • 仅6例可评估12个月或以上的输血独立状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Renizgamglogene autogedtemcel (reni-cel) is an investigational clustered regularly interspaced short palindromic repeats (CRISPR)-Cas12a gene-edited autologous hematopoietic stem-cell therapy. The therapy was designed to disrupt the BCL11A binding sites in the HBG1 and HBG2 promoters to reactivate fetal hemoglobin production for the treatment of transfusion-dependent β-thalassemia. METHODS: We conducted a phase 1-2, multicenter, open-label, single-group study of reni-cel in participants 18 to 35 years of age with transfusion-dependent β-thalassemia. The participants received myeloablative conditioning with busulfan before reni-cel infusion. The primary end points were neutrophil engraftment by 42 days after infusion and frequency and severity of adverse events. Participants were monitored for hemoglobin-related measures and transfusion independence. The study was terminated early on the basis of the sponsor's reassessment of clinical development priorities. Results of an analysis that was not prespecified are reported. RESULTS: Nine participants with transfusion-dependent β-thalassemia (four β0/β0 or β0/β0-like and five non-β0/β0 genotypes) received reni-cel and were included in the analysis. The median duration of postinfusion follow-up was 17.5 months (range, 3.8 to 23.4), and six participants could be evaluated for transfusion independence at 12 months or more. All the participants had neutrophil and platelet engraftment by 42 days after infusion. Rapid increases in total and fetal hemoglobin levels resulted in each of the nine participants being transfusion-free at their last follow-up visit. The six participants who could be evaluated at 12 months or later were transfusion-independent. The mean total and fetal hemoglobin levels were greater than 12 g per deciliter and greater than 11 g per deciliter, respectively, between months 6 and 18. A total of 69 grade 3 or 4 adverse events with onset or worsening during or after reni-cel infusion were reported in the nine participants. Six serious adverse events (infections, pyrexia, or pneumonitis) were reported in four participants. Adverse events were generally consistent with myeloablative conditioning. One patient had decreased lymphocyte counts attributed to reni-cel. CONCLUSIONS: Treatment with reni-cel resulted in rapid neutrophil engraftment, an increase in fetal hemoglobin expression, and transfusion independence. These data support further investigation of Cas12a gene editing of the promoters of HBG1 and HBG2 in the treatment of transfusion-dependent β-thalassemia. (Funded by Editas Medicine; EdiThal ClinicalTrials.gov number, NCT05444894.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Frangoul H, Hanna R, Walters MC, et al. CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia. N Engl J Med. 2026. PMID: 41931048. doi:10.1056/NEJMoa2501277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。